Back to Search Start Over

Pretransplant Hepatic Malignancy Increases Risk of De Novo Malignancy after Liver Transplantation.

Authors :
Park GC
Hwang S
Ahn CS
Kim KH
Moon DB
Ha TY
Song GW
Jung DH
Yoon YI
Cho HD
Kwon JH
Chung YK
Kang SH
Choi JU
Jung IJ
Lee SG
Source :
Journal of Korean medical science [J Korean Med Sci] 2020 Mar 23; Vol. 35 (11), pp. e69. Date of Electronic Publication: 2020 Mar 23.
Publication Year :
2020

Abstract

Background: Hepatocellular carcinoma (HCC) recurrence and development of de novo malignancy (DNM) after liver transplantation (LT) are the major causes of late recipient death.<br />Methods: We analyzed the incidence of extrahepatic DNM following living donor LT according to the status of pretransplant hepatic malignancy. We selected 2,076 adult patients who underwent primary LDLT during 7 years from January 2010 to December 2016.<br />Results: The pretransplant hepatic malignancy group (n = 1,012) showed 45 cases (4.4%) of the following extrahepatic DNMs: posttransplant lymphoproliferative disease (PTLD) in 10; lung cancer in 10; stomach cancer in 6; colorectal cancer in 5; urinary bladder cancer in 3; and other cancers in 11. The pretransplant no hepatic malignancy group (n = 1,064) showed 25 cases (2.3%) of the following extrahepatic DNMs: colorectal cancer in 3; stomach cancer in 3; leukemia in 3; lung cancer in 3; PTLD in 2; prostate cancer in 2; and other cancers in 9. Incidences of extrahepatic DNM in the pretransplant hepatic malignancy and no hepatic malignancy groups were as follows: 1.1% and 0.5% at 1 year, 3.2% and 2.0% at 3 years, 4.6% and 2.5% at 5 years, and 5.4% and 2.8% at 8 years, respectively ( P = 0.006). Their overall patient survival rates were as follows: 97.3% and 97.2% at 1 year, 91.6% and 95.9% at 3 years, 89.8% and 95.4% at 5 years, and 89.2% and 95.4% at 8 years, respectively ( P < 0.001). Pretransplant hepatic malignancy was the only significant risk factor for posttransplant extrahepatic DNM.<br />Conclusion: Our results suggest that patients who had pretransplant hepatic malignancy be followed up more strictly because they have a potential risk of primary hepatic malignancy recurrence as well as a higher risk of extrahepatic DNM than patients without pretransplant hepatic malignancy.<br />Competing Interests: The authors have no potential conflicts of interest to disclose.<br /> (© 2020 The Korean Academy of Medical Sciences.)

Details

Language :
English
ISSN :
1598-6357
Volume :
35
Issue :
11
Database :
MEDLINE
Journal :
Journal of Korean medical science
Publication Type :
Academic Journal
Accession number :
32193900
Full Text :
https://doi.org/10.3346/jkms.2020.35.e69